- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.08. | Greenwich LifeSciences, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 10.08. | Greenwich LifeSciences Stock Gains 4% After Extending Share Lock-Up | 5 | RTTNews | ||
| 10.08. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027 | 488 | GlobeNewswire (Europe) | STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 22.07. | Greenwich LifeSciences gains UK approval for breast cancer trial | 1 | Investing.com | ||
| 22.07. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom | 333 | GlobeNewswire (Europe) | STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| GREENWICH LIFESCIENCES Aktie jetzt für 0€ handeln | |||||
| 20.07. | Greenwich LifeSciences: Aktie erholt sich nach detailliertem Update zur FLAMINGO-01-Studie | 1 | Investing.com Deutsch | ||
| 20.07. | Greenwich LifeSciences passt Studiendesign für Brustkrebs-Vakzin an - Aktie bricht ein | 2 | Investing.com Deutsch | ||
| 20.07. | Greenwich LifeSciences updates phase III breast cancer trial design | 2 | Investing.com | ||
| 20.07. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01 | 553 | GlobeNewswire (Europe) | STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 16.07. | Greenwich LifeSciences expands trial enrollment in Europe | 2 | Investing.com | ||
| 16.07. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01 | 256 | GlobeNewswire (Europe) | STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 09.07. | EMA-Zulassung für GP2 beflügelt Aktie von Greenwich LifeSciences | 1 | Investing.com Deutsch | ||
| 09.07. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 | 583 | GlobeNewswire (Europe) | STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 04.06. | Greenwich LifeSciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.06. | Greenwich LifeSciences, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 01.06. | Greenwich LifeSciences presents immune response data at ASCO | 1 | Investing.com | ||
| 01.06. | Greenwich LifeSciences delays 10-K filing, cites audit coordination | 1 | Investing.com | ||
| 01.06. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update Regarding Form 10-K Filing | 278 | GlobeNewswire (Europe) | STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 22.05. | Greenwich LifeSciences receives Nasdaq noncompliance notice | 1 | Investing.com | ||
| 22.05. | NASDAQ rügt Greenwich LifeSciences wegen Nichteinhaltung von Berichtspflichten | 3 | Investing.com Deutsch |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,00 | -0,12 % | Biontech-Standorte offenbar vor dem Aus | Idar-Oberstein/Tübingen/Marburg - Die Biontech-Standorte in Idar-Oberstein, Tübingen und Marburg stehen offenbar vor dem Aus. Wie der SWR und der HR am Montag berichten, habe sich für die Werke keine... ► Artikel lesen | |
| NOVAVAX | 9,230 | -0,65 % | Novavax Inc mit PAUKENSCHLAG: Droht die Aktie jetzt der nächste Absturz? - Jetzt unbedingt lesen! | ||
| INOVIO PHARMACEUTICALS | 1,067 | +3,09 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,600 | 0,00 % | Viking Therapeutics - Herausforderer im Milliardenmarkt für Abnehmmedikamente | Starke VK2735-Daten, Phase-3-Studien und eine orale Variante eröffnen Viking enormes Potenzial - bei weiterhin hohen klinischen und finanziellen Risiken. Der weltweite Markt für Medikamente gegen Adipositas... ► Artikel lesen | |
| INFLARX | 1,533 | -0,45 % | InflaRx N.V.: InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development | Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,900 | 0,00 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| EDITAS MEDICINE | 2,210 | -5,15 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,411 | +4,05 % | 90 Milliarden US-Dollar bis 2030: Wie Bayer, Mesoblast und NurExone regenerative Medizin unterschiedlich entwickeln | ||
| ABIVAX | 82,40 | 0,00 % | EQS-News: ABIVAX: Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
30.09.2026 / 22:05 CET/CEST
The... ► Artikel lesen | |
| KUROS BIOSCIENCES | 19,960 | -0,30 % | PAUKENSCHLAG bei Kuros Biosciences: Steht die Aktie vor einem Kursdesaster? - Das müssen Sie am Montag wissen! | ||
| IBIO | 0,963 | -3,60 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| GERON | 1,095 | +3,06 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| IMMUNITYBIO | 9,110 | -0,33 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 6,690 | -0,74 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 4,004 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial | SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been... ► Artikel lesen |
Das Unternehmen GREENWICH LIFESCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,47 % bei einem Aktienkurs von 16,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GREENWICH LIFESCIENCES INC finden Sie auf Wallstreet Online.